Subscribe To
KZR / Should You Buy Kezar (KZR) Ahead of Earnings?
KZR News
By Zacks Investment Research
October 4, 2023
Kezar (KZR) Falls 10% on Strategic Update, Reduces Workforce
Kezar (KZR) falls 10% on the decision to channel resources to one clinical candidate as part of its reprioritization efforts and slash the workforce b more_horizontal
By Business Wire
January 4, 2023
Kezar Life Sciences to Present at the 41st Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif.--( BUSINESS WIRE )--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and develo more_horizontal
By Seeking Alpha
November 16, 2022
Kezar Life Sciences: Mid-Term Growth Levers Heavily Discounted, Reduce To Hold
Following a shift in market sentiment, I've narrowed my rating for Kezar Life Sciences from buy to hold. The market has heavily discounted KZR's growt more_horizontal
By Zacks Investment Research
June 30, 2022
Wall Street Analysts Think Kezar Life Sciences, Inc. (KZR) Could Surge 135%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 135.4% in Kezar Life Sciences, Inc. (KZR). While the effectiv more_horizontal
By Schaeffers Research
June 28, 2022
Biotech Stock Blasts Higher After Upbeat Trial Data
Kezar Life Sciences Inc (NASDAQ:KZR) is skyrocketing today, up 84.1% at $10.55, after positive results from a mid-stage study of its kidney disorder d more_horizontal
By Benzinga
June 27, 2022
After-Hours Action: Why Kezar Life Sciences Stock Is Soaring
Kezar Life SciencesĀ Inc (NASDAQ: KZR) shares are surging in Monday's after-hours session after the company announced topline results from the MISSION more_horizontal
By Zacks Investment Research
May 10, 2022
Should You Buy Kezar (KZR) Ahead of Earnings?
Kezar (KZR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season. more_horizontal